News
- Author:
- Susan London
Publish date: November 15, 2017
When it comes to the adverse effects of tyrosine kinase inhibitors, hypothyroidism appears to have a bright side.
News
- Author:
- Susan London
Publish date: November 6, 2017
Experience is more predictive than ultrasound in evaluating pediatric thyroid nodules.
News
- Author:
- Susan London
Publish date: October 29, 2017
VICTORIA, B.C. – Monthly medication costs for the brand-name drug were more than twice that of the generic drug.
News
- Author:
- Susan London
Publish date: October 26, 2017
VICTORIA, B.C. – Hypothyroid lengthens recovery surgery beyond time predicted by surgical risk calculator.
News
- Author:
- Susan London
Publish date: October 26, 2017
VICTORIA, B.C. – Can you say placebo effect?
News
- Author:
- Susan London
Publish date: October 23, 2017
Keep methimazole on board to prevent Graves’ relapse after remission.
News
- Author:
- Susan London
Publish date: October 22, 2017
Graves’ orbitopathy is more likely to respond to combination therapy than monotherapy,
News
- Author:
- Susan London
Publish date: October 21, 2017
Benefit may be overestimated because previous studies weren’t blinded.
News
- Author:
- Susan London
Publish date: October 3, 2017
The study is the first to examine time to DMARD therapy adjustment and time to low disease activity for RA patients with moderate to high disease a...
Article
- Author:
- Susan London
Publish date: September 7, 2017
News
- Author:
- Susan London
Publish date: August 28, 2017
Enasidenib monotherapy was well tolerated and active in a phase 1/2 trial involving patients with relapsed or refractory IDH2-mutated AML.
News
- Author:
- Susan London
Publish date: August 8, 2017
Sequential treatment with pazopanib and everolimus yields a median overall survival exceeding 2 years in predominantly older and sicker patients wi...
News
- Author:
- Susan London
Publish date: August 3, 2017
Of 23 new primary cancers found through screening in 20 patients, 10 belonged to the core LFS spectrum of breast cancer, sarcoma, and brain tumors....
News
- Author:
- Susan London
Publish date: July 18, 2017
Patients in the signature-defined high-risk group had roughly twice the adjusted risk of death as that of those in the signature-defined low-risk g...
News
- Author:
- Susan London
Publish date: July 5, 2017
Young women treated for early hormone receptor–positive, HER2-negative breast cancer fare better if their adjuvant endocrine therapy includes ovari...
